Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 1—January 2012

Letter

Mumps Vaccine Effectiveness Against Orchitis

Susan HahnéComments to Author , Jane Whelan, Rob van Binnendijk, Corien Swaan, Ewout Fanoy, Hein Boot, and Hester de Melker
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands

Main Article

Table

Mumps complications by MMR vaccination status, the Netherlands, December 1, 2009–June 14, 2011*

Complication MMR doses received No. mumps cases No. (%) cases with complications OR aOR† p value Adjusted VE,‡ % (95% CI)
Orchitis§ 0 86 20 (23) Ref Ref Ref Ref
1 48 5 (10) 0.38 0.34 0.05 66 (1 to 88)
2 338 31 (9) 0.32 0.26 <0.01 74 (49 to 87)
Other complications¶ 0 117 1 (1) Ref Ref Ref Ref
1 85 1 (1) 1.38 0.88 0.93 12 (–14 to 95)
2 571 6 (1) 1.23 0.75 0.80 25 (–5 to 91)
Hospitalization 0 130 4 (3) Ref Ref Ref Ref
1 83 2 (2) 0.80 0.70 0.69 30 (–312 to 88)
2 535 6 (1) 0.40 0.43 0.25 57 (–84 to 90)

*Only those for whom complication and vaccination status were known are included; therefore, totals may differ. MMR, mumps, measles, rubella; OR, odds ratio; aOR, adjusted odds ratio; VE, vaccine effectiveness; ref, reference categories.
†OR and VE adjusted for age group (<18, 18−25, >25 y) and sex, except for orchitis, where the OR and VE were adjusted only for age group.
‡VE = 1 – OR where the OR is an approximation of the relative risk.
§Only men ≥12 years of age are included.
¶Includes the following reported complications: pancreatitis (n = 2), meningitis (3), thyroiditis (1), bronchitis (1), high fever and shortness of breath (1).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO